Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain

References

• BoyleITBones for the futureActa Paediatr Scand Suppl19918037358651927530
   PubMedGoogle Scholar
• McClungMRThe menopause and HRT. Prevention and management of osteoporosisBest Pract Res Clin Endocrinol Metab2003171537112763512
   PubMed Web of Science ®Google Scholar
• McNamaraLMPerspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fracturesJ R Soc Interface201074435337219846441
   PubMed Web of Science ®Google Scholar
• BianchiMLOrsiniMRSaraifogerSOrtolaniSRadaelliGBettiSQuality of life in post-menopausal osteoporosisHealth Qual Life Outcomes200537816321148
   PubMedGoogle Scholar
• MarquisPCialdellaPDe la LogeCDevelopment and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOSTQual Life Res200110655556611789555
   PubMed Web of Science ®Google Scholar
• CalvoEMorcilloDForuriaAMRedondo-SantamariaEOsorio-PicorneFCaeiroJRGEIOS-SECOT Outpatient Osteoporotic Fracture Study GroupNondisplaced proximal humeral fractures: high incidence among outpatient-treated osteoporotic fractures and severe impact on upper extremity function and patient subjective health perceptionJ Shoulder Elbow Surg201120579580121195633
   PubMed Web of Science ®Google Scholar
• Sanfelix-GenovesJHurtadoISanfelix-GimenoGReig-MollaBPeiroSImpact of osteoporosis and vertebral fractures on quality-of-life. A population-based study in Valencia, Spain (the FRAVO study)Health Qual Life Outcomes201192021470396
   PubMed Web of Science ®Google Scholar
• AdkinsJKassianosGIbandronate – a convenient and effective treatment option for the management of post-menopausal osteoporosisDrugs Context200842121134
   Google Scholar
• AkaNBalkanEZeynep Tuzcular VuralEYaziciogluEThe risk factors in postmenopausal osteoporosisMarmara Medical Journal2000134219222
   Google Scholar
• Diaz CurielMGarciaJJCarrascoJLPrevalence of osteoporosis assessed by densitometry in the Spanish female populationMed Clin (Barc)200111638688 Spanish11181284
   PubMed Web of Science ®Google Scholar
• CiprianiCRomagnoliEMinisolaSPharmacological treatment of osteoporosis – old and new drugsEur Musculoskelet Rev2011628387
   Google Scholar
• ColeZDennisonECooperCUpdate on the treatment of post-menopausal osteoporosisBr Med Bull200886112914318477578
   PubMed Web of Science ®Google Scholar
• SammartinoACirilloDMandatoVDDi CarloCNappiCOsteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapyJ Endocrinol Invest20052810 Suppl808416550729
   PubMedGoogle Scholar
• Viktoria SteinKDornerTLawrenceKKunzeMRiederAEconomic concepts for measuring the costs of illness of osteoporosis: an international comparisonWien Med Wochenschr20091599–10253261 German19484209
   PubMedGoogle Scholar
• BouzaCLopezTPalmaMAmateJMHospitalised osteoporotic vertebral fractures in Spain: analysis of the National Hospital Discharge RegistryOsteoporos Int200718564965717221295
   PubMed Web of Science ®Google Scholar
• PueyoMJLarrosaMSurisXGarcia-RuizAJCost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in CataloniaReumatol Clin20128312813422421456
   PubMedGoogle Scholar
• RizzoliRBisphosphonates for post-menopausal osteoporosis: are they all the same?QJM2011104428130021258058
   PubMed Web of Science ®Google Scholar
• CavalliLBrandiMLTargeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utilityTher Clin Risk Manag2012825326622745560
   PubMed Web of Science ®Google Scholar
• AdamiSFelsenbergDChristiansenCEfficacy and safety of ibandronate given by intravenous injection once every 3 monthsBone200434588188915121020
   PubMed Web of Science ®Google Scholar
• KremerRNew targets for osteoporosisPresented at the International Symposium on Multidisciplinary Approaches to Modern Therapeutics Joining Forces for a Healthier TomorrowMay 24–27, 2011Montreal, QC, Canada
   Google Scholar
• BoyleWJSimonetWSLaceyDLOsteoclast differentiation and activationNature2003423693733734212748652
   PubMed Web of Science ®Google Scholar
• PolaEColangeloDFuscoAEfficacy of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and orthopaedic surgeons and clinical resultsJ Orthopaed Traumatol201112Suppl 1S1S22
   Google Scholar
• PrzedlackiJStrontium ranelate in post-menopausal osteoporosisEndokrynol Pol2011621657221365582
   PubMed Web of Science ®Google Scholar
• CorradoAQuartaLErricoSCantatoreFPSuccessful treatment of avascular bone necrosis of the knee with neridronate: a case reportRheumatol Int200727989189317285278
   PubMed Web of Science ®Google Scholar
• CotteFECortetBLafumaAA model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in FranceJoint Bone Spine200875220120817988921
   PubMed Web of Science ®Google Scholar
• CotteFEDe PouvourvilleGCost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in FranceBMC Health Serv Res20111115121702989
   PubMed Web of Science ®Google Scholar
• PayerJCiernyDKillingerZSulkovaIBehuliakMCelecPPreferences of patients with post-menopausal osteoporosis treated with bisphosphonates – the VIVA II studyJ Int Med Res20093741225122919761708
   PubMed Web of Science ®Google Scholar
• Sicras-MainarANavarro-ArtiedaRGutierrezLSorioFIntorciaMPersistence to postmenopausal osteoporosis (PMO) treatments in a region of SpainValue Health2010137A380
   Google Scholar
• KaramustafaFCelebiNBisphosphonates and alendronateFABAD J Pharm Sci20063113142
   Google Scholar
• PerazellaMAMarkowitzGSBisphosphonate nephrotoxicityKidney Int200874111385139318685574
   PubMed Web of Science ®Google Scholar
• BorromeoGLBrandCClementJGIs bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyBMC Musculoskelet Disord2011127121477374
   PubMed Web of Science ®Google Scholar
• Perez EdoLAlonso RuizARoig VilasecaDUpdate of the consensus statement of the Spanish Society of Rheumatology on osteoporosisReumatol Clin201176357379 Spanish22078694
   PubMedGoogle Scholar
• JonssonBStromOEismanJACost-effectiveness of denosumab for the treatment of postmenopausal osteoporosisOsteoporos Int201122396798220936401
   PubMed Web of Science ®Google Scholar
• StromOBorgstromFSenSSCost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries – an economic evaluation based on the Fracture Intervention TrialOsteoporos Int20071881047106117333449
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellOOdenAJonssonBDawsonADereWRisk of hip fracture derived from relative risks: an analysis applied to the population of SwedenOsteoporos Int200011212012710793869
   PubMed Web of Science ®Google Scholar
• De LaetCEvan HoutBABurgerHHofmanAPolsHABone density and risk of hip fracture in men and women: cross sectional analysisBMJ199731571022212259253270
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJAOdenAPredictive value of BMD for hip and other fracturesJ Bone Miner Res20052071185119415940371
   PubMed Web of Science ®Google Scholar
• KlotzbuecherCMRossPDLandsmanPBAbbottTA3rdBergerMPatients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res200015472173910780864
   PubMed Web of Science ®Google Scholar
• SimonJARecknorCMoffettAHJrImpact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fractureMenopause201320213013723010883
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Nursing and Supportive CareSystematic reviews of clinical effectiveness prepared for the guideline ‘Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk’London, UKNational Institute for Health and Clinical Excellence2008 Available from: https://www.nice.org.uk/guidance/cg146/documents/osteoporosis-evidence-reviews2Accessed January 16, 2015
   Google Scholar
• BoonenSAdachiJDManZTreatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high riskJ Clin Endocrinol Metab20119661727173621411557
   PubMed Web of Science ®Google Scholar
• McClungMBoonenSTorringOEffect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisJ Bone Miner Res201227121121821976367
   PubMed Web of Science ®Google Scholar
• HemminkiADmitrievILiuBDesmondRAAlemanyRCurielDTTargeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion moleculeCancer Res200161176377638111522629
   PubMed Web of Science ®Google Scholar
• HiligsmannMBoonenADirksenCDBen SedrineWReginsterJYCost-effectiveness of denosumab in the treatment of postmenopausal osteoporotic womenExpert Rev Pharmacoecon Outcomes Res2013131192823402442
   PubMed Web of Science ®Google Scholar
• HiligsmannMReginsterJYCost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in BelgiumPharmacoeconomics2011291089591121692551
   PubMed Web of Science ®Google Scholar
• Alvarez-NebredaMLJimenezABRodriguezPSerraJAEpidemiology of hip fracture in the elderly in SpainBone200842227828518037366
   PubMed Web of Science ®Google Scholar
• IsmailAAPyeSRCockerillWCIncidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS)Osteoporos Int200213756557112111017
   PubMed Web of Science ®Google Scholar
• MarinFGonzalez-MaciasJMoyaRFragility non-spinal fractures in a cohort of 5,201 women aged 65 years and older during a 3-year follow-upMed Clin (Barc)200612711401404 Spanish17020682
   PubMed Web of Science ®Google Scholar
• Naves DiazMDiaz LopezJBGomez AlonsoCAltadill ArreguiARodriguez RebollarACannata AndiaJBStudy of incidence of osteoporotic fractures in a cohort of individuals older than 50 years from Asturias, Spain, after a 6 year follow-up periodMed Clin (Barc)200011517650653 Spanish11141414
   PubMed Web of Science ®Google Scholar
• EPOS Study GroupIncidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS)J Bone Miner Res200217471672411918229
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellODe LaetCJonssonBExcess mortality after hospitalisation for vertebral fractureOsteoporos Int200415210811214598026
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellODe LaetCJonssonBOglesbyAKThe components of excess mortality after hip fractureBone200332546847312753862
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de EstadisticaPopulation figures and demographic censuses2011 Available from: http://www.ine.es/inebmenu/mnu_cifraspob.htm#6Accessed January 16, 2015 Spanish
   Google Scholar
• BarrettJABaronJABeachMLMortality and pulmonary embolism after fracture in the elderlyOsteoporos Int2003141188989412942231
   PubMed Web of Science ®Google Scholar
• ParkerMJAnandJKWhat is the true mortality of hip fractures?Public Health199110564434461803403
   PubMed Web of Science ®Google Scholar
• GisbertRBrosaMSpanish Health Costs Database 2011 Available from http://www.oblikue.com/bddcostes/Accessed January 16, 2015
   Google Scholar
• Consejo General de Colegios Oficiales de FarmacéuticosPortalfarma2014 Available from http://www.portalfarma.com/inicio/botplus20/Paginas/Bot-PLUS-2-0.aspxAccessed January 16, 2015
   Google Scholar
• BaztanJJCaceresLALlanqueJLGavidiaJJRuiperezIPredictors of functional recovery in older hospitalized adultsJ Am Geriatr Soc201260118718922239317
   PubMed Web of Science ®Google Scholar
• De la Torre GarcíaMRodríguez PérezJCMoreno MoreuNJacintoRLHernández SantanaADeive MaggioloJCEconomic impact study of the hip fractures in our midstTrauma2012231 Spanish
   Google Scholar
• Lopez-BastidaJOlivaJAntonanzasFSpanish recommendations on economic evaluation of health technologiesEur J Health Econ201011551352020405159
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellOOdenAThe risk and burden of vertebral fractures in SwedenOsteoporos Int2004151202614593450
   PubMed Web of Science ®Google Scholar
• PeasgoodTHerrmannKKanisJABrazierJEAn updated systematic review of health state utility values for osteoporosis related conditionsOsteoporos Int200920685386819271098
   PubMed Web of Science ®Google Scholar
• KanisJACooperCHiligsmannMRabendaVReginsterJYRizzoliRPartial adherence: a new perspective on health economic assessment in osteoporosisOsteoporos Int201122102565257321617992
   PubMed Web of Science ®Google Scholar
• FreemantleNSatram-HoangSTangETFinal results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal womenOsteoporos Int201223131732621927922
   PubMed Web of Science ®Google Scholar
• LandfeldtEStromORobbinsSBorgstromFAdherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA)Osteoporos Int201223243344321286686
   PubMed Web of Science ®Google Scholar
• CaulinFKanisJAJohnellOOdenAOptimal age for preventing osteoporosis after menopause depends on effects of stopping treatmentBone200230575475811996915
   PubMed Web of Science ®Google Scholar
• JonssonBKanisJDawsonAOdenAJohnellOEffect and offset of effect of treatments for hip fracture on health outcomesOsteoporos Int199910319319910525710
   PubMed Web of Science ®Google Scholar
• HaradaAAbsolute risk for fracture and WHO guideline. Economic analysis of pharmacotherapy for osteoporosisClin Calcium200717710291034 Japanese17607069
   PubMedGoogle Scholar
• KanisJABorgstromFZethraeusNJohnellOOdenAJonssonBIntervention thresholds for osteoporosis in the UKBone2005361223215663999
   PubMed Web of Science ®Google Scholar
• MullinsCDOhsfeldtRLModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapyJ Manag Care Pharm20039215015814613344
   PubMedGoogle Scholar
• StromOBorgstromFKanisJAJonssonBIncorporating adherence into health economic modelling of osteoporosisOsteoporos Int2009201233418521650
   PubMed Web of Science ®Google Scholar
• BorgstromFZethraeusNJohnellOCosts and quality of life associated with osteoporosis-related fractures in SwedenOsteoporos Int200617563765016283064
   PubMed Web of Science ®Google Scholar
• ZethraeusNStromCMBorgstromAWhat is the risk of institutionalization after hip fracture?Osteoporosis Int200617Suppl 2S60
   Google Scholar
• Sanfelix-GenovesJReig-MollaBSanfelix-GimenoGThe population-based prevalence of osteoporotic vertebral fracture and densitometric osteoporosis in postmenopausal women over 50 in Valencia, Spain (the FRAVO study)Bone201047361061620601286
   PubMed Web of Science ®Google Scholar
• De CockEMiravitllesMRamón González-JuanateyJRamón Azanza-PereaJThreshold of cost per life year gained to recommend the adoption of health technologies in Spain: evidence from a review of the literaturePharmacoeconomics – Spanish Research Articles20074397107 Spanish
   Google Scholar
• SacristanJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit2002164334343 Spanish12113733
   PubMedGoogle Scholar
• OusterhoutMMBlaserDAGagnonJCost-effectiveness comparative analysis of bisphosphonates for the treatment of post-menopausal osteoporosisPresented at the 16th Annual International Meeting of the International Society of Pharmacoeconomics and Outcomes ResearchMay 21–25, 2011Baltimore, MD, USA
   Google Scholar
• LippunerKPollockRFSmith-PalmerJMeuryTValentineWJA review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in SwitzerlandAppl Health Econ Health Policy20119640341721910511
   PubMedGoogle Scholar
• MuellerDGandjourACost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosisAppl Health Econ Health Policy20119425927321682353
   PubMedGoogle Scholar
• IglesiasCPTorgersonDJBearneABoseUThe cost utility of bisphosphonate treatment in established osteoporosisQJM200295530531111978902
   PubMed Web of Science ®Google Scholar
• MaggiSPasqualeMBouinOModeled cost-effectiveness of rise-dronate versus ibandronate: the case of ItalyJ Bone Miner Res200823SupplS213
   Google Scholar
• BorgstromFCarlssonASintonenHThe cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspectiveOsteoporos Int2006177996100716570118
   PubMed Web of Science ®Google Scholar
• BorgstromFStromOKlemanMCost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspectiveOsteoporos Int201122395596520532482
   PubMed Web of Science ®Google Scholar
• KimKSvedbomALuoXSutradharSKanisJAComparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithmOsteoporos Int201425132533724114398
   PubMed Web of Science ®Google Scholar
• HartWMRubio-TerresCBurrellAAristeguiIEscobar-JimenezFPharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronateRevista Espanola de Enfermedades Metabolicas Oseas200211397104 Spanish
   Google Scholar
• AthanasakisKKarampliEHollandezosMA cost-effectiveness analysis of denosumab for the treatment of post-menopausal osteoporosis in GreeceValue Health2011147A308
   Web of Science ®Google Scholar
• CristinoJCanhaoHPerelmanJSantosCPereiraJCost-utility analysis of denosumab versus standard care in the treatment of post-menopausal osteoporosis in PortugalPoster presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes ResearchMay 21–25, 2011Baltimore, MD, USA
   Google Scholar
• ParthanADeflinMMYurginNHuangJTaylorDCCost-effectiveness of denosumab versus oral bisphosphonates in the United States for post-menopausal osteoporosis (PMO)Abstract PMS26 presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes ResearchJune 2–6, 2012Washington, DC, USA
   Google Scholar
• ChauDBeckerDLCoombesMEIoannidisGAdachiJDGoereeRCost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in CanadaJ Med Econ201215Suppl 131423035625
   PubMedGoogle Scholar
• AnastasilakisADToulisKAPolyzosSAAnastasilakisCDMakrasPLong-term treatment of osteoporosis: safety and efficacy appraisal of denosumabTher Clin Risk Manag2012829530622767993
   PubMed Web of Science ®Google Scholar
• PapapoulosSLippunerKRouxCEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extensionJ Osteoporosis Int20142524647
   Google Scholar
• National Insitute of Health and Clinical ExcellenceAlendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended), 2011 Available from: http://www.nice.org.uk/guidance/ta161Accessed January 16, 2015
   Google Scholar
• InderjeethCAFooACLaiMMGlendenningPEfficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidenceBone200944574475119130909
   PubMed Web of Science ®Google Scholar
• Imaz IglesiaIAnálisis coste-utilidad de los tratamientos farmacológicos para la prevención de fracturas en mujeres con osteoporosis en EspañaIPE 63/2010Agencia de Evaluación de Tecnologías Sanitarias. Instituto de Salud Carlos IIIMadrid2010
   Google Scholar